Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence
LONDON, June 2, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions.
As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence and Derwent Innovation Index.
By bringing together world-class data and insights from academic research and the life sciences and healthcare sectors, the agreement empowers researchers and practitioners at all levels — including scholars, policy advisors, biomedical scientists and healthcare professionals — to conduct innovative research, develop new treatments, improve patient care, and inform policy decisions. It provides broad access to critical information, advancing evidence-based discovery, education and decision-making across disciplines.
Matti Shem Tov, Chief Executive Officer, Clarivate, said:"This expanded partnership with CAPES is a powerful example of how strategic collaboration can accelerate research and innovation on a national scale. Brazil has made remarkable progress in advancing scientific excellence and global collaboration. We're proud to support this momentum by providing trusted data, insights, and technology to researchers across the country — from early discovery through impact assessment. Our shared commitment to expanding access and fostering innovation will continue to shape the future of research in Brazil and beyond."
Denise Pires de Carvalho, President, CAPES, said: "Brazil is experiencing a moment of growing scientific output beyond its major urban centers, with resources now being distributed in a more equitable and democratic way to boost productivity across all regions. This collaboration with Clarivate enables us to better understand the scientific production profile of Brazilian institutions and supports more informed investment decisions to reduce regional disparities, which remains a significant national challenge. Many researchers in the North, Northeast and Center-West have limited access to the resources needed to give visibility to their work and expanding that access can make a meaningful difference."
The renewed partnership reflects a shared commitment to democratizing access to critical scientific information and enabling data-driven research excellence. Through Web of Science, Journal Citation Reports, and Derwent Innovation Index, academic institutions and government agencies gain deeper visibility into global research trends, publication impact, and innovation pathways — supporting policy development, institutional benchmarking, and scholarly advancement.
Complementing these capabilities, expanded access to Cortellis Drug Discovery Intelligence equips Brazil's life sciences community — including postgraduate students, faculty, and biomedical researchers — with comprehensive insights across biology, pharmacology, and chemistry. From disease understanding and drug interactions to clinical studies and intellectual property, users can more efficiently navigate the full R&D lifecycle and accelerate decision-making in high-impact research areas.
By significantly expanding access to trusted research and innovation tools, this agreement supports CAPES' mission to reduce regional disparities and foster inclusive academic excellence. Institutions from across Brazil — from leading urban universities to those in underserved and remote regions — can now leverage high-quality data to strengthen postgraduate programs, accelerate innovation, and elevate the global visibility of Brazilian research.
Clarivate values its collaboration with CAPES on this initiative to help shape a more connected, informed and future-ready research ecosystem across Brazil, and stands as a resource for academic consortia worldwide seeking to expand access to trusted research, data and insights.
To learn more about this partnership and the solutions now available to CAPES institutions, visit here.
Notes to editors
According to the most recent Institute for Scientific Information G20 research and innovation scorecard:
Around 40% of Brazilian research output is internationally collaborative, with many strong bilateral partnerships with the United States. It also participates in larger collaborations involving the U.S., the U.K., Spain, Germany, and France. Compared with other internationally collaborative output, these partnerships are producing papers with above average impact.
Its research output shows a strong focus on Sustainable Development Goals (SDGs) Zero Hunger (SDG 2) and Life on Land (SDG 15), with impact for both around 0.7 to 0.8 times the world average.
More broadly, Brazilian research output has a strong focus on the Life Sciences, while its output in Medicine has impact around 1.1 times the world average.
Around 40% of output is published in open access (OA) journals, with their Humanities and Languages output 2.4 times more likely to be published in an OA journal than the G20 average.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) is a consortium dedicated to expanding and strengthening postgraduate studies in Brazil. It ensures the quality of academic programs while fostering the development of highly qualified professionals in research, teaching, and other strategic scientific fields.
Media contacts:
Clarivate
Catherine Daniel
Director, External Communications – Life Sciences & Healthcare
[email protected]
CAPES
João Mendes
Communications
[email protected]
SOURCE Clarivate Plc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
The China Fund, Inc. Announces Board Approval of Plan of Liquidation
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- The China Fund, Inc. (NYSE: CHN) (the 'Fund') announced today that its Board of Directors (the 'Board') has approved a plan of liquidation and dissolution (the 'Plan') for the Fund. The Plan will be submitted to Fund stockholders for approval at a Special Meeting. The date of the Special Meeting and more detailed information about the proposed liquidation and Plan will be set forth in a proxy statement to be mailed to the Fund's stockholders in the near future. The Board recommends that the Fund's stockholders vote for the liquidation of the Fund at the Special Meeting. In determining to liquidate the Fund, the Board considered a variety of factors including, among others, prevailing geopolitical and market conditions, the size of the Fund, the trading volume of the Fund's shares, the Fund's discount to net asset value, and the availability of competing open-end products, such as exchange-traded funds. The Board also considered alternatives, including converting the Fund into an open-end management investment company. On balance, the Board determined that the liquidation of the Fund is in the best interests of the Fund and its stockholders. The Fund intends to file a proxy statement with the U.S. Securities and Exchange Commission (the 'SEC') with respect to the proposal to liquidate the Fund. As noted, copies of the Fund's proxy statement will also be mailed to each stockholder of record of the Fund. Upon receipt, stockholders are advised to read the Fund's proxy statement as it will contain important information. Once filed with the SEC, the proxy statement will be available free of charge on the SEC website, This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the Fund's current plans and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning such risks and uncertainties are contained in the Fund's regulatory filings, which are available free of charge on the SEC's website. An investment in the Fund involves risk, including loss of principal. Investment return and the value of shares will fluctuate. Any data and commentary provided in this press release are for informational purposes only. The Fund is a closed-end management investment company. The Fund's investment manager is Matthews International Capital Management, LLC. For further information regarding the Fund, please call (888)-CHN-CALL or visit the Fund's website at The information contained on the Fund's website is not part of this press release. Copies of the Fund's complete audited financial statements are available free of charge upon request. Investments involve risk, including possible loss of principal, and an investment should be made with an understanding of the risks involved with owning a particular security or asset class. Interested parties are strongly encouraged to seek advice from qualified tax and financial experts regarding the best options for your particular circumstances. Contact
Globe and Mail
5 hours ago
- Globe and Mail
Fiverr: A Stock Analysis Amid Rising AI Competition
Explore the exciting world of Fiverr (NYSE: FVRR) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 12, 2025. The video was published on Jun. 20, 2025. Should you invest $1,000 in Fiverr International right now? Before you buy stock in Fiverr International, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Fiverr International wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Cision Canada
6 hours ago
- Cision Canada
Statement from Dennis Darby, President & CEO, Canadian Manufacturers & Exporters regarding passage of C-5, the One Canadian Economy Act, in the House of Commons
OTTAWA, ON, June 20, 2025 /CNW/ - Canadian Manufacturers & Exporters (CME) welcomes today's passage of Bill C-5, the One Canadian Economy Act, through the House of Commons. This legislation marks a meaningful first step toward fixing Canada's fragmented and inefficient approach to infrastructure approvals - one that has held back investment, delayed major projects, and weakened our economic competitiveness. From highways and ports to pipelines and clean energy infrastructure, Canada needs to get major projects moving - faster. Bill C-5 can help pave the way for clearer oversight, reduced duplication and greater government accountability, all of which are vital building the infrastructure our economy depends on. But this is only the beginning. The passage of Bill C-5 must not be the end of the conversation - it must be the starting point for a broader transformation. The federal government must now turn its attention to a much harder task: tackling the underlying web of outdated legislation, regulatory inefficiencies, and policy contradictions that have made a bill like this necessary in the first place. Until those deeper barriers are addressed, Canada will continue to struggle to attract private sector investment in the kinds of projects - big and small, urban and rural - that create jobs, grow communities, and position our economy for long-term success. Manufacturers are looking for outcomes, not just intentions. We look forward to the Bill passing in the Senate so that we can build on this momentum and do the hard work needed to truly unlock Canada's potential. About Canadian Manufacturers & Exporters (CME) From the first industrial boom in Canada, CME has advocated for and represented member interests. 150 years strong, CME has earned an extensive and effective track record of working for thousands of leading companies nationwide. More than 85 per cent of CME's members are SMEs and collectively account for an estimated 82 per cent of total manufacturing production and 90 per cent of Canada's exports.
